Key Highlights

  • Celldex Therapeutics, Inc. reported positive results from two phase 3 trials, EMBARQ-CSU1 and EMBARQ-CSU2.
  • The trials enrolled 963 and 976 patients respectively with chronic spontaneous urticaria.
  • Complete response rates at 24 weeks ranged from 45.1 to 54.0 percent on barzolvolimab versus 15.4 to 17.6 percent on placebo.
  • CEO Anthony Marucci said the results showed efficacy that is best-in-disease, with a BLA submission planned for 2027.

Strong Results Across Two Large Trials

Celldex Therapeutics, Inc. reported positive results from two phase 3 trials of its monoclonal antibody barzolvolimab in chronic spontaneous urticaria, a chronic hives condition, with EMBARQ-CSU1 enrolling 963 patients and EMBARQ-CSU2 enrolling 976 patients. At 12 weeks, complete response rates, defined as a UAS7 score of zero, ranged from 42.4 to 45.7 percent on barzolvolimab compared with just 9.3 to 12.6 percent on placebo, with the gap widening further by 24 weeks to 45.1 to 54.0 percent on barzolvolimab versus 15.4 to 17.6 percent on placebo.

Efficacy in the Hardest-to-Treat Patients

Among patients who had not responded adequately to omalizumab, a standard existing therapy for chronic spontaneous urticaria, 41.7 to 55.3 percent achieved complete response at week 12 on barzolvolimab compared with just 9.3 to 15.1 percent on placebo, a particularly meaningful result given that this omalizumab-refractory population represents patients with the fewest existing effective treatment options. Efficacy of this magnitude in a treatment-refractory population is generally viewed as especially significant clinical evidence, since it demonstrates the drug's potential value beyond patients who might have responded to existing therapies regardless.

Leadership Confidence and Next Steps

Celldex co-founder, president, and Chief Executive Officer Anthony Marucci said the results showed efficacy that is best-in-disease in chronic spontaneous urticaria, a strong characterization that reflects the company's confidence in barzolvolimab's competitive positioning relative to existing and emerging therapies in the category. The company plans to submit a Biologics License Application in 2027, giving investors a concrete regulatory timeline to track as the drug moves toward potential commercialization.

Where Things Stand

Celldex's strong phase 3 results for barzolvolimab across two large chronic spontaneous urticaria trials, including notable efficacy in omalizumab-refractory patients, position the drug as a potentially best-in-disease therapy ahead of a planned 2027 BLA submission. Continued execution toward that regulatory filing will likely remain the key milestone investors track for the company going forward.